Product Information
THEOPHYLLINE ER 300 MG TABLET is a generic product labeled by Chartwell RX LLC, priced at $0.3295 per EA under NDC 62135045790. Its NADAC has been published 178 times since May 10, 2023.
FDA first approved this application on Apr 30, 1990. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The Low Outlier badge above means this manufacturer's average price in the Theophylline market falls below Q1 − 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
300 mg/1
Manufacturer
Chartwell RX LLCNDC
62135045790
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
THEOPHYLLINE ANHYDROUSApproval Type
Generic (ANDA)
FDA Application
ANDA089763FDA Approved
4/30/1990
TE Code
AB
On Market Since
6/27/2022
Pharmacological Classes
Price Statistics
The NADAC for THEOPHYLLINE ER 300 MG TABLET has been published 178 times since May 10, 2023, and over the history we have for it it has declined 84.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.3295 per EA |
|---|---|
| All-time high | $2.6814 (Jun 14, 2023) |
| All-time low | $0.3196 (May 20, 2026) |
| 52-week high | $0.4924 |
| 52-week low | $0.3196 |
| Median price | $0.6050 |
| Average price | $0.9843 |
| Largest weekly change | +88.5% (Aug 21, 2024) |
| Weeks tracked | 178 |
| Tracking since | May 10, 2023 |
Generic Alternatives
The matcher finds 9 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Chartwell RX LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Theophylline market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Methylxanthine class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of THEOPHYLLINE ER 300 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for THEOPHYLLINE ER 300 MG TABLET, manufactured by Chartwell RX LLC, is $0.3295 per EA (NDC 62135045790), effective Sep 30, 2026.
How has the price of THEOPHYLLINE ER 300 MG TABLET changed over time?
Over the history we have for it, the NADAC for THEOPHYLLINE ER 300 MG TABLET has declined 84.9%. It has been tracked across 178 weekly CMS publications since May 10, 2023.
What are the highest and lowest recorded NADAC prices for THEOPHYLLINE ER 300 MG TABLET?
Since May 10, 2023, the NADAC for THEOPHYLLINE ER 300 MG TABLET has ranged from a low of $0.3196 (May 20, 2026) to a high of $2.6814 (Jun 14, 2023), with a median of $0.6050 per EA.
Are there cheaper alternatives to THEOPHYLLINE ER 300 MG TABLET?
9 manufacturers publish a NADAC-priced product with the same active ingredient and strength as THEOPHYLLINE ER 300 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures THEOPHYLLINE ER 300 MG TABLET?
THEOPHYLLINE ER 300 MG TABLET (NDC 62135045790) is labeled by Chartwell RX LLC, and CMS classifies it as a generic product.